## COO: The Cooper Companies, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.2% in lower entry zone (3.0-6.0%), top quartile (83rd pct) cross-sectional ranking. Short-term MRS_5 (2.4%) confirms momentum alignment. Momentum building (+0.6% 5-day). Outperforming sector by 6.5%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($76.87)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Cooper Companies (COO) Valuation: Reassessing Upside After Earnings Beat, Strong 2026 Outlook and Strategic Review**
- Source: Simply Wall Street | 20251209T130758 | Somewhat-Bullish | Relevance: 96%
- Cooper Companies (COO) recently announced an earnings beat, a strong 2026 outlook, and a strategic review, leading to an 11.32% share price recovery over 30 days, despite a substantial 21.38% drop over the last year. The company is currently considered 6% undervalued, trading at $78.04 against a fair value estimate of $83.00, driven by anticipated free cash flow generation and debt reduction. However, a high P/E ratio and pressure in the contact lens and fertility markets pose risks to the recovery.

**2. Cooper Companies (COO) Valuation: Reassessing Upside After Earnings Beat, Strong 2026 Outlook and Strategic Review**
- Source: Simply Wall Street | 20251209T123914 | Somewhat-Bullish | Relevance: 96%
-  Cooper Companies (COO) recently announced an earnings beat, a positive 2026 outlook, and a strategic review, leading to an 11.32% stock return over 30 days. Despite a negative 21.38% return over the past year, the company's free cash flow is expected to rise by $2 billion over three years, positioning it as slightly undervalued at $78.04 against a fair value of $83. However, pricing pressure and weakness in specific market segments could cap its recovery upside.

**3. Alcon Announces Amended Merger Agreement with STAAR Surgical**
- Source: Business Wire | 20251209T131017 | Bullish | Relevance: 65%
-  Alcon has announced an amended merger agreement to acquire STAAR Surgical for $30.75 per share in cash, a total equity value of approximately $1.6 billion. This follows STAAR's "go-shop" period, during which no superior offers emerged. Alcon urges STAAR stockholders to approve the transaction by December 19, 2025, emphasizing the value for stockholders and the opportunity to broaden access to STAAR's technology.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 10, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Citigroup | $88 | $72 | +22% |
| 2025-12-08 | Morgan Stanley | $83 | $76 | +9% |
| 2025-12-08 | Goldman Sachs | $71 | $64 | +11% |
| 2025-12-05 | Stifel | $95 | $85 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Citigroup | main | Neutral |
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Goldman Sachs | main | Sell |
| 2025-12-05 | Stifel | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.14M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-1.1%)
- Blackrock Inc.: 7.7% (-0.8%)
- Capital World Invest: 5.3% (+25.7%)
- T. Rowe Price Invest: 4.9% (+33.2%)
- State Street Corpora: 4.3% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 10 raises (avg +14%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.87 indicates undervaluation relative to growth. Analyst sentiment positive (10 raises, avg +14%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.3B |
| Beta | 1.05 |
| 52W Range | $61.78 - $100.24 |
| Short Interest | 4.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.87 |
| Forward P/E | 16.6 |
| Current P/E | 18.2 |
| YoY Growth | 9.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.6% over 5 days). Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 83rd percentile. MRS_5 at 2.4% confirms short-term momentum alignment. Outperforming sector by 6.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.17% (CS: 83) | Strong |
| RSI_14 | 68.0 | Neutral |
| MACD Histogram | 0.44 | Bullish |
| vs SMA20 | 1.078x | Above |
| vs SMA50 | 1.124x | Above |
| vs SMA200 | 1.100x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $82.11
- **Stop Loss:** $76.87 (6.4% risk)
- **Target:** $89.97 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 263
- **Position Value:** $21,594.93
- **Portfolio %:** 21.59%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-03-05 (Est: $1.03)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.11 | $1.15 | +3.3% |
| 2025Q3 | $1.07 | $1.10 | +3.0% |
| 2025Q2 | $0.93 | $0.96 | +3.3% |
| 2025Q1 | $0.91 | $0.92 | +0.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*